

11-13-03

Docket No: AM100986

Patent

UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of:

Ronald Charles BERNOTAS et al.

Application No.:

10/621,698

Group Art No.:

1614

Filed:

July 17, 2003

Examiner:

For:

1-HETEROCYCLYLALKYL-3-SULFONYLINDOLE OR

-INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6

LIGANDS

Confirmation No.:

1509

Customer Number:

25291

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

1. **Preliminary Statements**

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV243963355US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Carole K. Kamrad

Docket No: AM100986 Patent

2.		Identification of Time of Filing									
		is Information Disclosure Statement									
	a. b.	is filed within three months of the filing date of the application. is filed before the mailing date of a first Office Action on the merits.									
	о. С.	is filed before the mailing date of a first Office Action of the filing of a									
	U.	request for continued examination under 37 CFR 1.114.									
	d.	is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).									
	e.	is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).									
3.		Certification under 37 CFR 1.97(e) and 1.704(d) The undersigned attorney certifies									
	a.	that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the									
	b.	filing of the statement, or that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification									
	с.	after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement. The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.									
	\boxtimes	Newly Cited Information A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed.									
		Previously Cited Information No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.									
		Prior application is Application Number , filed on of for .									

Docket No: AM100986
Patent

a. b.							
Form	PTO-1449 is enclosed in duplicate.						
	Fees Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00						
Char	Method of Payment of Fees: Charge Deposit Account No. 01-1425 in the amount of \$0.00 A duplicate of this statement is enclosed.						
Instructions as to Overpayment/Underpayment: Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.							
Santour Less							
	Barbara L. Lences						
	Agent for Applicants Reg. No. 41,148						

Wyeth Patent Law Department Five Giralda Farms Madison, NJ 07940 Tel. No. (732) 274-4678

STATE OF THE PROPERTY.	Complete if Known		
Substitute for form 1449/PTO	Application Number	10/621,698	
INFORMATION DISCLOSURE 1 2003	Filing Date	July 17, 2003	
STATEMENT BY APPLICANT NO	First Named Inventor	Ronald Charles Bernotas	
(use as many sheets as necessary)	Group Art Unit	1614	
Sur a TOROS	Examiner Name		
Sheet 1 of 1	Attorney Docket Number	AM100986	

	U.S. PATENT DOCUMENTS								
Examiner Cite Initials* No.		U.S. Patent Document Number Kind Code (If known) (If Known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			

	FOREIGN PATENT DOCUMENTS									
Examiner	Cite No.	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant			
Initials*		Office	Number	Kind Code (If Known)	Applicant of Cited document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T		
	1.	PCT	WO97 49698	A	GLAXO GROUP LTD.	12-31-1997				
	2.	PCT	WO97 49699	Α	GLAXO GROUP LTD	12-31-1997	•			
	3.	PCT	WO97 49382	A	GLAXO GROUP LTD	12-31-1997				
	4.	PCT	WO03 013510A	A	SMITHKLINE BEECHAM P.L.C.	02-20-2003				

		OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т

Examiner	Date	
Signature	Considered	